Skip to main navigation
Skip to search
Skip to main content
Research Nebraska Home
Help & FAQ
Home
Profiles
Research units
Facilities and Equipment
Research output
Projects
Activities
Prizes
Search by expertise, name or affiliation
The intergroup rhabdomyosarcoma study: Update, November 1978
H. M. Maurer
Pediatrics Hematology/Oncology
Research output
:
Contribution to journal
›
Article
›
peer-review
76
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The intergroup rhabdomyosarcoma study: Update, November 1978'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Dactinomycin
100%
Rhabdomyosarcoma
100%
Cyclophosphamide
75%
Irradiation
75%
Tumor
50%
Local Recurrence
25%
Excision
25%
Working Diagnosis
25%
Drug Combination
25%
Advanced Stage
25%
Adriamycin
25%
Metastatic Disease
25%
Diagnosis-related Groups
25%
After Surgery
25%
Chemotherapy Regimen
25%
Surgery Groups
25%
Tumor Regression
25%
Poor Prognosis
25%
Tumor Bed
25%
Residual Disease
25%
Overall Survival Rate
25%
Relapse-free Survival
25%
Intensive Chemotherapy
25%
Distant Recurrence
25%
Medicine and Dentistry
Dactinomycin
100%
Rhabdomyosarcoma
100%
Vincristine
100%
Neoplasm
75%
Cyclophosphamide
75%
Survival Rate
50%
Metastatic Carcinoma
25%
Recurrent Disease
25%
Malignant Neoplasm
25%
Doxorubicin
25%
Overall Survival
25%
Pulse Rate
25%
Chemotherapy Regimens
25%
Minimal Residual Disease
25%
Recurrence Free Survival
25%
Tumor Regression
25%
Combination Drug
25%
Pharmacology, Toxicology and Pharmaceutical Science
Rhabdomyosarcoma
100%
Vincristine
100%
Dactinomycin
100%
Neoplasm
75%
Cyclophosphamide
75%
Survival Rate
50%
Metastasis
25%
Malignant Neoplasm
25%
Recurrent Disease
25%
Overall Survival
25%
Doxorubicin
25%
Chemotherapy Regimens
25%
Combination Drug
25%
Minimal Residual Disease
25%
Tumor Regression
25%
Recurrence Free Survival
25%